📬 GYN Oncology Intelligence Digest — Week 2026-W30

KEYNOTE-C93 shows pembrolizumab monotherapy beats platinum doublet chemotherapy on PFS in frontline dMMR endometrial cancer, PORTEC-4a lets molecular profiling spare radiotherapy, and new ASCO ovarian guidelines and cervical cancer analyses land this week.

⚡ TL;DR

📄 Publications

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. — Disease control rate 38% and objective response rate 11%, with null 15% DC rate rejected (P=.004)
Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer. — Median OS was 25.1 months in both cisplatin and carboplatin groups (HR 0.98, 95% CI 0.81-1.18; P=.35)

🐦 Twitter / 🦋 Bluesky

PORTEC-4a: molecular-guided adjuvant therapy safely spares radiotherapy in high-intermediate-risk endometrial cancer — 46% of patients safely avoided adjuvant radiotherapy under molecular-guided treatment
KEYNOTE-C93: pembrolizumab monotherapy beats platinum doublet on PFS in frontline dMMR endometrial cancer — Phase 3 KEYNOTE-C93 showed pembrolizumab monotherapy significantly improved PFS vs platinum-based chemotherapy in previously untreated dMMR advanced or recurrent endometrial cancer
feMMe: LNG-IUD gives durable disease control in atypical endometrial hyperplasia and Grade 1 endometrioid cancer — 63% achieved pCR at 6 months, 64% maintained response, 24% recurrence after pCR, 50% live birth among those attempting conception
PYNNACLE: rezatapopt shows activity in TP53 Y220C-mutated advanced ovarian cancer — In 48 evaluable patients with TP53 Y220C-mutated advanced ovarian cancer, ORR was 46% with DOR of 8 months
Bevacizumab and platinum choice in pembrolizumab-treated advanced cervical cancer — Cisplatin and carboplatin provided equivalent survival; bevacizumab improved early OS but the benefit decreased over time

Full details below ↓

📄 What's Being Published

Manuscripts:

Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0. — Lesnock Jamie L et al., J Clin Oncol

The updated ASCO living guideline addresses recurrent ovarian cancer across platinum-sensitivity strata. For patients with platinum-resistant or refractory high-grade epithelial ovarian cancer (EOC) and validated folate receptor alpha (FRα) expression, mirvetuximab soravtansine is strongly recommended. For patients with recurrent platinum-sensitive EOC, clinicians should offer platinum-based combination regimens, specifically pegylated liposomal doxorubicin plus carboplatin, paclitaxel plus carboplatin, or gemcitabine plus carboplatin.

Clinical bottom line: The updated ASCO living guideline anchors recurrent ovarian cancer treatment on platinum-based doublets for platinum-sensitive disease and strongly recommends mirvetuximab soravtansine for FRα-expressing platinum-resistant disease.

Read full article →

Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling program. — Domènech Heura et al., NPJ Precis Oncol

HRD was more frequent in high-grade ovarian cancer (52%) than in metastatic breast cancer (12%) or prostate cancer (20%). Longitudinal ctDNA sequencing revealed BRCA1/BRCA2 reversion mutations in more than 30% of post-PARPi metastatic breast cancer samples, which were associated with poor response to subsequent platinum therapy.

Clinical bottom line: Complementary RAD51 and genomic instability testing in tissue and liquid biopsy detect HRD missed by genetic testing and track BRCA reversion, supporting broader biomarker panels to guide PARP inhibitor use.

Read full article →

Preoperative PARP Inhibitors in Ovarian Cancer Trials: Connecting Molecular Oncology and Cytoreductive Surgery. — Miedziarek Cezary et al., Cancers (Basel)

This review examines the rationale and current evidence for PARP inhibitor administration prior to cytoreductive surgery in ovarian cancer. Preoperative PARP inhibitor therapy is characterized as theoretically promising but an unproven strategy in ovarian cancer, with hematologic toxicity and surgical delay identified as key concerns.

Clinical bottom line: Preoperative PARP inhibition before cytoreductive surgery in ovarian cancer remains investigational, with hematologic toxicity and surgical delay as key concerns awaiting prospective trials with surgery-specific endpoints.

Read full article →

Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer. — Farolfi Alberto et al., JAMA Netw Open

In pembrolizumab-treated advanced cervical cancer, median OS was 25.1 months in both the cisplatin and carboplatin groups (HR 0.98, 95% CI 0.81–1.18; P=.35), indicating equivalent survival across platinum agents. Bevacizumab addition was associated with a 12-month OS of 74.8% (95% CI, 70.4%–79.2%) versus 64.5% (95% CI, 59.8%–69.2%) without bevacizumab, though the 24-month OS figures converged at 56.2% (95% CI, 50.9%–61.5%) versus 54.0% (95% CI, 48.7%–59.3%), respectively.

Clinical bottom line: In pembrolizumab-treated advanced cervical cancer, cisplatin and carboplatin gave equivalent survival while bevacizumab produced an early OS benefit that attenuated over time.

Read full article →

🔗 Also discussed on social media →

Molecular Profiling of Tisotumab Vedotin-Treated Patients Identifies Immune Pathways Associated With Clinical Activity. — Sridhar Sriram et al., Clin Cancer Res

Although tissue factor (TF) expression is required for tisotumab vedotin binding to tumor cells, clinical responses were found to be independent of TF levels. Higher expression of gene signatures linked to natural killer cells and myeloid cells was associated with improved clinical outcomes.

Clinical bottom line: Tisotumab vedotin activity in recurrent/metastatic cervical cancer is driven by a multimodal immune-effector mechanism rather than tissue factor level, supporting ADC efficacy in tumors with heterogeneous target expression.

Read full article →

Intermittent olaparib with neoadjuvant platinum-based chemotherapy in BRCA-mutated un-resectable ovarian cancer: the NUVOLA trial. — Salutari Vanda et al., Int J Gynecol Cancer

Among 35 patients who received at least two cycles of neoadjuvant therapy, complete pathological response was achieved in three patients (8.6%), with an overall response rate of 89% assessed prior to interval debulking surgery. At a median follow-up of 42.9 months, median PFS was 39.7 months (95% CI, 22.4 to not reached) and median OS was not reached (95% CI, 47.6 to not reached).

Clinical bottom line: Concurrent intermittent olaparib with neoadjuvant chemotherapy did not increase complete pathological response in BRCA-mutated ovarian cancer, suggesting PARP inhibitor benefit is driven by post-chemotherapy maintenance.

Read full article →

Cost-effectiveness of a bevacizumab biosimilar for the treatment of recurrent, platinum-sensitive ovarian cancer in the United States. — Seguin Claudia L et al., Gynecol Oncol

Adding brand-name bevacizumab increased total costs and median survival to $362,206 and 3.52 years, respectively, resulting in an ICER of $399,400/LYG. Substituting bevacizumab-awwb for the brand-name agent reduced total costs to $252,512 and the ICER to $131,900/LYG versus chemotherapy alone.

Clinical bottom line: A bevacizumab biosimilar makes bevacizumab cost-effective in recurrent platinum-sensitive ovarian cancer at a $150,000/LYG threshold, unlike the brand-name agent.

Read full article →

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. — Veljovich Dan S et al., JCO Precis Oncol

Three patients had a partial response and seven had SD16+ for disease control and objective response rates of 38% (90% CI, 25 to 100) and 11% (95% CI, 2 to 29), respectively; the null hypothesis of a 15% disease control rate was rejected (P=.004). Median PFS was 8 weeks (95% CI, 8 to 18) and median OS was 33 weeks (95% CI, 24 to 73).

Clinical bottom line: Palbociclib met the prespecified activity threshold in ovarian cancer with CDKN2A alterations, signaling a candidate targeted option in this molecularly defined subgroup.

Read full article →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

PORTEC-4a: molecular-guided adjuvant therapy safely spares radiotherapy in high-intermediate-risk endometrial cancer

In PORTEC-4a, molecular profiling using POLE, MMRd, NSMP, and p53abn subtypes guided adjuvant treatment decisions in high-intermediate-risk endometrial cancer, with non-inferior vaginal recurrence compared with standard treatment. Notably, 46% of patients safely avoided adjuvant radiotherapy under the molecular-guided approach. The central debate is whether molecular classification should now routinely determine which patients receive adjuvant radiotherapy and which can be spared.

Discussed by: @ChandrakanthMv, @power4patients

→ View representative tweet

KEYNOTE-C93: pembrolizumab monotherapy beats platinum doublet on PFS in frontline dMMR endometrial cancer

The phase 3 KEYNOTE-C93 trial showed pembrolizumab monotherapy significantly improved progression-free survival compared with platinum-based chemotherapy in patients with previously untreated advanced or recurrent endometrial cancer with dMMR tumors. Oncologists noted, however, that the comparator was chemotherapy alone rather than chemo plus immunotherapy, and that GY018 and RUBY had already moved dMMR endometrial cancer to chemo plus IO combinations with HRs of approximately 0.30–0.35 — meaning beating chemotherapy alone is not equivalent to matching a chemo plus IO backbone. The clinical question is how to sequence a chemo-free frontline pembrolizumab option against existing chemo plus IO standards in the dMMR population.

Discussed by: @OncoAlert, @DrBarbiOnc, @EladSharonMD, @IJGConline, @CancerNetwrk, @MAvilaMD

→ View representative tweet

feMMe: LNG-IUD gives durable disease control in atypical endometrial hyperplasia and Grade 1 endometrioid cancer

The feMMe trial data show that the levonorgestrel-releasing intrauterine device (LNG-IUD) can provide durable disease control in selected women with atypical endometrial hyperplasia and Grade 1 endometrioid adenocarcinoma: 63% achieved complete pathological response at 6 months, 64% maintained response long-term, and among those attempting conception, 50% achieved a live birth. The 24% recurrence rate after complete pathological response frames the core debate around whether fertility-sparing LNG-IUD management offers sufficiently durable disease control in this setting.

Discussed by: @OncoAlert, @IJGConline

→ View representative tweet

PYNNACLE: rezatapopt shows activity in TP53 Y220C-mutated advanced ovarian cancer

In 48 evaluable patients with TP53 Y220C-mutated advanced ovarian cancer enrolled in the PYNNACLE study, rezatapopt demonstrated an ORR of 46% and a duration of response of 8 months, characterized as rapid, durable, and broad antitumour activity in a heavily pretreated population where effective targeted therapies and biomarkers are limited. The practical question for oncologists is how testing pathways should be structured to identify the TP53 Y220C mutation and enable patient access to rezatapopt.

Discussed by: @womenofteal, @AinhoaMada

→ View representative tweet

Bevacizumab and platinum choice in pembrolizumab-treated advanced cervical cancer

A real-world analysis published in JAMA Network Open found that, in pembrolizumab-treated advanced cervical cancer, cisplatin and carboplatin provided equivalent survival, with median OS of 25.1 months in both groups (HR 0.98, 95% CI 0.81–1.18; P=.35). Bevacizumab addition improved early overall survival — 12-month OS 74.8% versus 64.5% without bevacizumab — but the benefit decreased over time, with 24-month OS figures converging at 56.2% versus 54.0%. Specialists are weighing whether this attenuating bevacizumab benefit and platinum equivalence should alter first-line pembrolizumab-chemotherapy backbone decisions in advanced cervical cancer.

Discussed by: @JAMANetworkOpen, @jamanetworkopen.com

→ View representative tweet

🔥 Top Ranked Tweets

Oncology Brothers @OncBrothers

2025 approvals: Summary of 5 new drugs/indications in #BreastCancer & #GynOnc by Santa aka @US_FDA

1. #DatoDXd
2. #TDXd x2
3. #Imlunestrant
4. #Avutometinib/#Defactinib: Ovarian Ca

#bcsm #OncTwitter #MedTwitter #HappyHolidays #MerryChristmas https://t.co/KPxaS5GWV9
[Quoting @OncBrothers: 2024 approvals: Summary of 8 new drugs/indications in #BreastCancer & #GynOnc by @US_FDA

1. #Ribociclib
2. #Inavolisib
3. #Pembrolizumab x2
4. #Mirvetuximab
5. #Tisotumab
6. #Dostarlimab
7. #Durvalumab

#bcsm #gyncsm #OncTwitter #MedTwitter #HappyHolidays https://t.co/SqUwyupgz1]

🔖 37 ❤️ 75 🔁 30 👁 13,242